Gilead Sciences GILD NASDAQ:GILD

Trading Conditions in Europe Remain Soft in TNT’s First Quarter

TNT Express’ first-quarter consolidated revenue fell 4.5% from the same period last year (down 4% excluding foreign exchange). The decline was partly the result of softer Asia Pacific business, including sluggish export activity to Europe. Price competition and a continued mix shift to loweryielding shipments in Europe also contributed. Excluding foreign exchange, revenue was down…

Read More

Biotech Stock Update: Amgen Stock Disappoints

Amgen (AMGN) suffered a major setback when its phase III study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) on multiple myeloma treatment, Kyprolis did not meet its primary endpoint. The open-label study evaluated Kyprolis versus an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients suffering from relapsed…

Read More